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Abstract
Background: Measurement of self-efficacy requires carefully developed and validated instruments. It is
currently unclear whether available self-efficacy instruments for chronic diseases fulfill these requirements.
Our aim was to systematically identify all existing self-efficacy scales for five major chronic diseases and to
assess their development and validation process.
Methods: We conducted a systematic literature search in electronic databases (MEDLINE, PSYCHINFO,
and EMBASE) to identify studies describing the development and/or validation process of self-efficacy
instruments for the five chronic diseases diabetes, chronic obstructive pulmonary disease (COPD),
asthma, arthritis, and heart failure. Two members of the review team independently selected articles
meeting inclusion criteria. The self-efficacy instruments were evaluated in terms of their development (aim
of instrument, a priori considerations, identification of items, selection of items, development of domains,
answer options) and validation (test-retest reliability, internal consistency reliability, validity,
responsiveness) process.
Results: Of 584 potentially eligible papers we included 25 (13 for diabetes, 5 for asthma, 4 for arthritis, 3
for COPD, 0 for heart failure) which covered 26 different self-efficacy instrument versions. For 8
instruments (30.8%), the authors described the aim before the scales were developed whereas for the
other instruments the aim was unclear. In one study (3.8%) a priori considerations were specified. In none
of the studies a systematic literature search was carried out to identify items. The item selection process
was often not clearly described (38.5%). Test-retest reliability was assessed for 9 instruments (34.6%),
validity using a correlational approach for 18 (69.2%), and responsiveness to change for 3 (11.5%)
instruments.
Conclusion: The development and validation process of the majority of the self-efficacy instruments had
major limitations. The aim of the instruments was often not specified and for most instruments, not all
measurement properties that are important to support the specific aim of the instrument (for example
responsiveness for evaluative instruments) were assessed. Researchers who develop and validate self-
efficacy instruments should adhere more closely to important methodological concepts for development
and validation of patient-reported outcomes and report their methods more transparently. We propose
a systematic five step approach for the development and validation of self-efficacy instruments.
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Background
The measurement of self-efficacy, a critical concept in
chronic disease management, is of increasing interest for
the assessment and management of patients with chronic
diseases. First, measurement of self-efficacy is helpful for
planning patient education programs because the identi-
fication of areas with low self-efficacy helps targeting self-
management education to the individual patient. Second,
measurement of changes in self-efficacy over time is
important to evaluate the impact of patient education
programs. Third, the measurement of self-efficacy is useful
to detect individual differences between patients, and
finally, measurement of self-efficacy may be an indicator
to predict important health outcomes such as hospital
admissions or health-related quality of life.
Perceived self-efficacy, or in brief self-efficacy, is the major
concept of Bandura's social cognitive theory. It is con-
cerned with an individual's belief in his or her capability
to produce given attainments [1-4]. The individual's per-
ception of his or her ability to perform an action is an
important mediator of health behaviors [3,5]. Perception
of self-efficacy is particularly important for complex activ-
ities and long-term changes in behavior and is considered
to be critical feature in chronic disease management [6-9].
There are substantial differences in what areas and to what
extent human beings develop self-efficacy. Measurement
of self-efficacy should be tailored to the relevant domains
of functioning that are of particular interest. Self-efficacy
scales capture patient judgments about their capability to
carry out given types of performances for selected activi-
ties and the strength of that belief [3,10].
As for the measurement of certain patient-reported out-
comes such as health-related quality of life [11], measure-
ment of self-efficacy requires the availability of carefully
developed and validated instruments. It is important that
the development process includes a clear definition of the
instrument's purpose and that domains relevant from the
patient's perspective are covered. For the validation proc-
ess, important measurement properties such as test-retest
reliability should be assessed [11]. Currently, it is unclear
whether available self-efficacy instruments for chronic
diseases fulfill these methodological quality criteria.
Therefore, the aim of this study was to systematically
assess the development and validation process of pub-
lished self-efficacy scales for the five major chronic dis-
eases diabetes, chronic obstructive pulmonary disease
(COPD), asthma, arthritis, and heart failure. They all
require complex activities like self-monitoring, an ade-
quate adaptation of medication, and long-term changes in
behavior where self-efficacy plays a critical role.
Methods
The review was conducted in two parts. First, a systematic
literature search was conducted to identify self-efficacy
instruments, and second, the identified instruments were
evaluated in terms of their development and validation
process.
Systematic literature search
Inclusion criteria
For the instrument search, following inclusion criteria
were applied:
1) Types of studies: Any cross-sectional or longitudinal
study to develop and validate self-efficacy instruments.
2) Type of instruments: Instruments (scales, question-
naires) that measure self-efficacy. To be included the
instruments must assess self-efficacy according to the fol-
lowing criteria [10]: a) Judgment of perceived capability
(the items should be phrased in terms of "can do" rather
than "will do" which is a statement of intention; e.g.
"How confident are you that you can..."). b) The items
must be linked to specific activities. c) The instruments
must include scales to quantify self-efficacy and the grad-
uation of challenge, respectively (e.g. "Please indicate on
a scale from 1 to 5 the degree to which you are confident
or certain that you can...").
3) Since we focused on the methods used for the develop-
ment and validation process of self-efficacy instruments, a
minimum of the development process had to be
described such as item identification, item selection or
construction of domains. Validation included any assess-
ment of test-retest reliability, cross-sectional or longitudi-
nal validity, internal consistency reliability, or
responsiveness.
4) Participants: Patients with COPD, asthma, arthritis,
diabetes (I and II), or heart failure. We did not have spe-
cific diagnostic criteria but accepted studies that included
patients with clinical diagnoses (e.g. asthma) or diagnoses
based on established criteria (e.g. FEV1/FVC <0.7 and FEV1
in % predicted <80%).
Exclusion criteria
Self-efficacy studies with another focus than development
and validation of a self-efficacy instrument.
We applied the following exclusion criteria:
1) Studies with use of a self-efficacy scale as an outcome
in intervention studies such as randomized trials, or stud-
ies looking at associations of self-efficacy with some other
outcomes such as hospital admissions.
2) Studies that translated an original instrument into a
different language or adapted it to another population.Health and Quality of Life Outcomes 2009, 7:86 http://www.hqlo.com/content/7/1/86
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Search Strategy
The electronic databases MEDLINE (Ovid), PSYCHINFO
(Ovid) and EMBASE (Elsevier) were searched. Self-efficacy
was first mentioned by Bandura in 1977. Therefore, eligi-
ble publications from 1977 until December 2007 (time of
search) were included. We used the following search
terms: "self-efficacy", "mastery", "copd", "emphysema",
"chronic bronchitis", "chronic airflow obstruction",
"asthma", "obstructive lung disease", "chronic airflow
limitation", "heart failure", "congestive/, heart failure",
"diabetes", "diabetes mellitus", "diabetes mellitus, type
2", "arthritis", "arthritis, reactive", "arthritis, rheumatoid",
"arthritis, juvenile rheumatoid", "scale", "questionnaire".
In addition, we performed hand searches using reference
lists of included studies and review articles. We also con-
tacted experts in the field to retrieve further articles.
Management of references
The bibliographic details of all retrieved articles were
stored in an Endnote file. Duplicate records resulting from
the various database searches were removed. The source of
identified articles (database, hand search, researcher con-
tacts) was recorded in a "user defined field" of the End-
note file.
Study selection
Two members of the review team (AF, AS) independently
assessed the titles and abstracts of all identified citations.
We applied no language restrictions. Decisions of the two
reviewers were recorded (order or reject) in the Endnote
file and then compared. Any disagreements were resolved
by consensus with close attention to the inclusion/exclu-
sion criteria. Two reviewers evaluated the full text of all
potentially eligible papers and made a decision whether
to definitely include or exclude each study according to
the inclusion and exclusion criteria specified above. Any
disagreements were resolved by consensus with close
attention to the inclusion/exclusion criteria and clarifica-
tion with a third and fourth reviewer (MP, CS). Final deci-
sions on papers were then recorded in the Endnote file. All
studies that did not meet the inclusion criteria were
excluded and their bibliographic details are listed together
with the reason for exclusion.
Instrument evaluation
After instrument identification we recorded the character-
istics of the self-efficacy scales using standard criteria and
analyzed their development and validation process
[11,12].
Characteristics of instruments
Aim of instrument
We distinguished 3 categories. First, if the aim of the
instrument was clearly specified by the authors before
development of the instrument, the classification was
"described". The described aims were classified as "evalu-
ative" (detection of changes in self-efficacy over time, typ-
ically for evaluation of treatments), "discriminative"
(detection of differences in self-efficacy between patients),
"predictive" (prediction of future health outcomes, e.g.
hospital admissions or death), and "planning" (planning
of treatment, e.g. detection of areas with low self-efficacy
to target patient education accordingly). Second, if the
aim was not explicitly described by the authors before
development but could be identified from the context, the
classification was "not clearly described, but presumably
(e.g. evaluative)". In case the purpose of the instrument
was not reported at all we used the classification "not
described".
Number of items, number and definition of domains
We extracted the number of items of each instrument and,
if applicable, the number of domains (subscales). We
refer to domains as important aspects of health and dis-
ease from the patients' perspective that can be measured
by a group of items that capture these aspects from differ-
ent angels.
Development of instruments
A priori consideration
We recorded whether the authors explicitly reported on a
priori considerations to base the development process
upon (specifications of domains to be covered, adminis-
tration format, time to complete questionnaire etc.). To
fulfill criteria, a priori considerations had to be explicitly
described in the section methods of the papers.
Identification of items
We recorded whether the identification process of the
potential items for the instrument was described using
any of the following sources: experts (e.g. through inter-
views with clinical experts, supplementation or modifica-
tion of existing items through experts), patients, patients'
parents, and literature. If the source of the identification
of the items was literature, we made a distinction between
a systematic literature search, an unsystematic search, and
no literature search but adaptation of an existing, specific
instrument.
Selection of items
We recorded the method used to select items for the final
instrument. We differentiated between data driven
approaches (e.g. use of statistical criteria using for exam-
ple factor analysis), patient approach (e.g. estimation of
frequency or importance of the items), and an expert
approach (e.g. estimation of relevance of the items by
clinical experts).
Definition of domains
We recorded the method of how the domains were
defined, i.e. if they were defined a priori (face validity
which items belong together, as judged for example byHealth and Quality of Life Outcomes 2009, 7:86 http://www.hqlo.com/content/7/1/86
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clinical experts) or if domains were defined by statistical
approaches such as factor analysis.
Answer options and instrument administration
We recorded the type of answer options for each instru-
ment (e.g. 7-point Likert type scale, visual analogue scale
0-100) and if the instrument was interviewer or self
administered.
Measurement properties
Test-retest
Any approaches to assess test-retest reliability (reproduci-
bility) were recorded, which may include intra-class corre-
lation coefficients, coefficient of variation, Pearson
correlation coefficient, or t-test.
Internal consistency reliability
The second measure for the reliability of the instruments
which was extracted was the assessment of internal con-
sistency reliability, for example by the use of Cronbach's
alpha, corrected item total correlation, and Cronbach's
alpha excluding item analysis.
Validity
We recorded approaches to assess validity that were con-
ducted after completion of the instrument development.
We extracted the method of validation and categorized
them as correlation approaches (e.g. assessment of corre-
lations with other self-efficacy scales, symptoms scales,
health related quality of life instruments, or other out-
comes) [13] or face validity (e.g. rating through experts).
Responsiveness
We recorded the approach to assess responsiveness, i.e.
the ability of an instrument to detect changes over time,
which may include calculation of effect sizes, a paired t-
Test, or Guyatt coefficient.
Data extraction strategy
Two reviewers (AF, AS) independently recorded details
about instrument characteristics and the development
and validation process according to the categories
described above in a predefined table, which we pretested
for using four randomly selected studies. The third and
fourth reviewer (MP, CS) resolved any discrepancies if the
two reviewers disagreed. Bibliographic details such as
author, journal, year of publication, and language were
also registered.
Methods of analysis and synthesis
We described the results of the data extraction in struc-
tured tables (Additional files) for each version of an
instrument according to the categories described above.
The aim of this compilation was to overview the character-
istics, development, and validation of the existing self-effi-
cacy instruments for patients with the chronic diseases
diabetes, COPD, asthma, arthritis, and heart failure. We
synthesized the data in a narrative way and used absolute
numbers and proportions to summarize the data quanti-
tatively using SPSS for Windows version (Version 16.0).
Results
Systematic literature search
Through electronic database search we identified 574
papers (Figure 1). After screening for title and abstracts,
502 papers were excluded. The main reason for this exclu-
sion was that self-efficacy scales were used as outcomes in
these studies. In addition to the resulting 72 papers from
database search, 10 papers were identified by hand
searches. Overall, we had 82 papers for full text assess-
ment, of which 57 papers were excluded. The most fre-
quent reasons for exclusion were no measurement of self-
efficacy or lack of clarity because of limited reporting (n =
26), translation/cultural adaptation of instruments (n =
14), review papers without original data (n = 4), or valida-
tion studies of existing instruments (n = 4). Finally, 25
papers could be included in the review [14-38].
The largest number of studies included patients with dia-
betes (n = 13) [17,19,20,23-27,30,31,33,35,36], followed
by asthma (n = 5) [16,22,32,34,37], arthritis (n = 4)
[14,15,21,28], and COPD (n = 3) [18,29,38]. No study
could be included for patients with heart failure.
The 25 papers covered 23 different self-efficacy instru-
ments. For three instruments, different versions were
developed: for the Self-Efficacy Score for Diabetes Scale
(SED) [17,20], the Maternal Self-Efficacy for Diabetes
Management Scale [26] and the Maternal Self-Efficacy for
Diabetes Scale [17] respectively, and the Insulin Manage-
ment Diabetes Self-Efficacy Scale (IMDSES) [19,23]. The
paper of Cullen et al. (2007) [17] incorporated the Self-
Efficacy Score for Diabetes Scale as well as the Maternal
Self-Efficacy for Diabetes Scale. Thus, the search resulted
in 26 different instrument versions.
Characteristics of instruments
The characteristics of the reviewed self-efficacy instru-
ments are summarized in Additional file 1.
Disease
The majority of the self-efficacy instrument versions was
developed for diabetes patients (n = 14). Five respectively
four instruments referred to asthma and arthritis patients
and three to patients with COPD.
Aim of instrument
For approximately one third of the self-efficacy instru-
ments (n = 8, 30.8%), the authors clearly described the
aim of the instruments before the scales were developed.Health and Quality of Life Outcomes 2009, 7:86 http://www.hqlo.com/content/7/1/86
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For 6 scales, one aim was described and for 2 scales more
than one. The most frequently described aims were evalu-
ative (n = 4) [28-30,37] and planning (n = 4)
[16,25,29,36], followed by discriminative (n = 2) [28,38].
Only one instrument had the aim a predictive [28]. For
42.3% of the instruments (n = 11), the authors did not
clearly describe the aim but it could be presumed out of
the context. In these cases, the most frequent aims was dis-
criminative (n = 7) [14,15,20,21,24,26,28,35], followed
by evaluative (n = 3) [18,21,22], and planning (n = 2)
[32,34]. For approximately one quarter of the scales (n =
7, 26.9%), the authors did not describe any aim of the
instrument before the development process began
[17,19,23,27,31,33].
Domains and number of items
There was great variability in the number of domains and
items across self-efficacy instruments. The number of
domains ranged from 1 to 8 with a median of 2 while the
number of items ranged from 5 to 80 with a median of
16.5. The domains varied also in terms of the areas they
covered. Most instruments cover disease-specific
domains, e.g. self-efficacy for managing or preventing
asthma attacks (e.g. "How sure are you that you can slow
yourself down to prevent serious breathing problems?"
[16]), self-efficacy for pain management in arthritis
patients (e.g. "How certain are you that you can keep
arthritis pain from interfering with your sleep?" [28]),
self-efficacy for blood sugar management in diabetes
patients (e.g. "I think I am able to remedy too high blood
sugar" [35]), or exercise self-regulatory efficacy in COPD
patients (e.g. "Please indicate the degree to which you are
confident or certain that you could continue to exercise
regularly (3 times a week for 20 minutes) when faced with
situations listed below (...)" [18]).
Development of self-efficacy instruments
Additional file 2 summarizes the development process of
the reviewed self-efficacy scales.
A priori consideration
A priori considerations were specified in one study (3.8%)
only [29]. They were described in the section "conceptual
framework" and included e.g. the characteristic of admin-
Flow diagram of process of systematic literature search Figure 1
Flow diagram of process of systematic literature search.
Full text assessment 
n = 82
- from database: 72 
- from hand search: 10 
Excluded
n = 502 
Included: n = 25
 Papers  Instruments 
Arthritis  n = 4  n = 4 
Asthma  n = 5  n = 5 
COPD  n = 3  n = 3 
Diabetes  n = 13  n = 11 
Heart failure  n = 0  n = 0 
Excluded: n = 57
- not measuring self-efficacy or uncertain  
if scale measures self-efficacy because 
of limited reporting    n = 26 
- translation/cultural adaptation  n = 14 
- background information n = 4 
- only validation     n = 4 
- application of scale    n = 2 
- no subscale of self-efficacy   n = 2 
- summary of other article   n = 1 
- comment on instrument  n = 1 
- article not found    n = 3
Title and abstract screening 
n = 574 Health and Quality of Life Outcomes 2009, 7:86 http://www.hqlo.com/content/7/1/86
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istration of the questionnaire, the definition of the
intended measurement, the hierarchical structure of the
instrument, and the conceptually derived components or
subscales.
Identification of items
The most common sources to identify items for self-effi-
cacy scales were the use and adaptation respectively of
items from existing self-efficacy or health related quality
of life instruments only without a literature search or fur-
ther input (4 instruments [17,19,23,32]) and unsystem-
atic literature searches in combination with input from
experts (4 instruments [22,30,35,36]), followed by input
from experts and patients without literature searches (for
3 instruments [21,28,33]). Overall, for the development
of 12 instruments, patients' opinion was considered, for
10 instruments it was not. In none of the studies a system-
atic literature search was carried out to identify items. For
4 instruments, the identification of items was unclear or
not reported at all [26,27,37,38].
Selection of items
In more than one third of the instruments, it is unclear or
not reported how the items for the scales were selected (n
= 10, 38.5%) [14-18,23,26,27,33,34]. For 6 instruments,
the selection was done data driven only (23.1%)
[17,19,25,28,32,38] and for 2 instruments (7.7%) [31,35]
by the input of experts only. For 8 instruments, more than
one approach of selection of items was used: experts and
data driven (n = 5, 19.2%) [21,24,29,30,37], and experts
and patients (n = 3, 11.5%) [20,22,36]. Most frequently,
the data driven approach was conducted by factor analy-
sis, the patient approach by the estimation of comprehen-
sibility of the items by patients, and the expert approach
by the estimation of relevance of the items by clinical
experts.
Development of domains
Approximately half of the domains of the instruments
were developed statistically by factor analysis (n = 14,
53.8%), for 9 instruments (34.6%) the domains were
developed a priori. In 3 cases, the development process of
domains was unclear or not reported (11.5%).
Validation of self-efficacy instruments
In Additional file 3, detailed information about the meas-
urement properties of the reviewed self-efficacy instru-
ments is summarized.
Test-retest
Test-retest reliability was assessed for only approximately
one third of the self-efficacy instruments (n = 9, 34.6%).
5 studies (19.2%) used Pearson correlation coefficient to
assess test-retest reliability [21,28,34-36], 2 studies
(7.7%) intra-class correlation coefficient [24,29], and 2
studies (7.7%) both t-test and Pearson correlation coeffi-
cient [23,38].
Internal consistency
For 24 instruments (92.3%) the internal consistency reli-
ability was tested, mostly by using Cronbach's alpha.
Validity
The majority of the instrument validations assessed valid-
ity (n = 18, 69.2%) and always followed a correlational
approach. Validation instruments varied across the differ-
ent disease groups. For example, self-efficacy scales for
diabetes patients were most frequently correlated with
physiological outcomes (for example HbA1c as a measure
of glycemic control) whereas health related quality of life
instruments were the predominant validation instru-
ments in the other disease groups.
Responsiveness
Responsiveness to change was assessed for 3 instruments
only (11.5%) [21,28,37] using t-tests and analysis of var-
iance. All of these instruments had an "evaluative" aim.
However, not all scales with an "evaluative" or a "presum-
ably evaluative" aim were tested for their responsiveness.
Discussion
Our systematic review showed that for some major
chronic diseases a substantial number of self-efficacy
instruments are available that cover disease- and task-spe-
cific aspects of self-efficacy. For diabetes, substantially
more self-efficacy instruments exist than for asthma,
arthritis, or COPD whereas for heart failure we did not
identify any instrument. Furthermore, the systematic
review indicated that development and validation process
of most instruments showed major methodological limi-
tations. The aim of the self-efficacy instrument was rarely
defined or specified, which might explain the suboptimal
quality of the development and validation processes.
Weaknesses of the development processes included unsys-
tematic approaches to identify potential items and
intransparent selection of the final items. The main limi-
tation of most validations was the failure to assess the
measurement properties that are important for the spe-
cific purpose of an instrument such as responsiveness for
evaluative instruments. Most validations focused on the
analysis of cross-sectional data sets, which is limited to the
assessment of internal consistency and cross-sectional
validity. Longitudinal measurement properties were rarely
assessed although some instruments had an evaluative
aim.
The strength of our review is the search approach to iden-
tify self-efficacy scales in literature. We conducted system-
atic database searches followed by a comprehensive handHealth and Quality of Life Outcomes 2009, 7:86 http://www.hqlo.com/content/7/1/86
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search. Hand searches are important because no standard-
ized indexing for self efficacy instruments exist. Further-
more, we applied a clearly defined methodological
framework to the data extraction. A limitation is that we
clearly focused on methodological aspects and not prima-
rily on the content of the instruments. We decided to do
so because judgment of the content was difficult since the
development process was frequently unclear. Although
we paid great attention to the inclusion of instruments
only that truly measure self-efficacy we cannot exclude the
possibility of having misclassified studies.
For the development and validation of new self-efficacy
instruments, two issues are crucial. First, one should use
rigorous and established methods for the development
and validation of patient-reported outcomes. Second, one
should consider the implications of Bandura's theoretical
concept which includes that self-efficacy instruments
should measure a judgment of perceived capability ("I can
do") for carrying out specific activities. However, we focus
our discussion on methodological aspects of patient
reported outcome measurement. A discussion of Ban-
dura's theoretical concept would be beyond the scope of
this article and we refer to his seminal work [3,10].
The methodological limitations of the development proc-
esses, which we discovered, implies that researchers often
seem to be unclear about what they want to measure with
the self-efficacy scales. For the development of a new
instrument it seems reasonable that the first step is to
clearly define the aim of the scale. The subsequent devel-
opment and validation process should then be designed
to fulfill and test the aim of the instrument. For example,
if the aim is evaluative, this is to detect change over time,
items should be selected that are modifiable and the
answer options should allow patients to express small but
important changes over time. Latter requires that the
answer scales offer a sufficient number of options so that
patients can express small but important changes [39].
The validation process must consider the measurement
properties that are important for evaluative instruments;
this is test-retest reliability, longitudinal validity, and
responsiveness. The development and validation process
should then be reported transparently in order to allow
potential users to assess whether or not the scale is ade-
quate for their purposes. In this systematic review, how-
ever, we observed that a substantial number of self-
efficacy scales were developed without a clear definition
of their aim.
We propose a systematic approach to the development
and validation process of new instruments as described in
Figure 2. First, the aim of the instrument should be
defined and described. This includes an explicit statement
if the instrument will primarily be used to assess change
over time, to find differences in self-efficacy between per-
sons (discriminative), to health outcomes (predictive), or
to support the planning of patient education programs
(step A).
Second, a priori considerations should be specified to
base the development process upon (step B). A priori con-
siderations include methodological and practical issues of
the questionnaire, which may include the number and
type of domains to be covered, the administration for-
mats, time to complete the questionnaire, and others.
The next step is the identification of items (step C). Com-
mon sources for item identification in the reviewed instru-
ments were existing scales, unsystematic literature
searches, and input from experts and patients. We recom-
mend beginning the identification process with a system-
atic literature search of existing instruments. Subsequent
input from patients is crucial in order to make sure that
the most relevant areas of potentially low self-efficacy are
included. The standard approach is to conduct focus
groups with patients and to use cognitive debriefing tech-
niques. Input from experts (physicians and qualified
health care workers) should be considered but one should
be careful to focus on what patients perceive to be impor-
tant and not what health care specialists suggest.
After identification, the selection process of the items fol-
lows (step D). We found that the item selection process
was often not clearly described. The most commonly used
methods, if reported, were patient-data driven selection of
items (using of statistical methods like factor analysis) or
a selection based on the opinion of experts. We recom-
mend, as for the item identification process, that the
patient perspective should be considered during the item
selection process.
The validation of the instrument is described in step E. In
our review most instrument validations focused on cross-
sectional data sets that often do not assess the measure-
ment properties that are important for the respective aim
of the instrument. For example, most validations included
internal consistency testing by Cronbach's alpha, but only
a minority of the studies conducted test-retest reliability
analyses. We recommend that the validation process must
include testing of the measurement properties that are rel-
evant to test the aim of the instrument. Every validation
should include an assessment of the test-retest reliability,
preferably by using intra-class correlation coefficients.
Because self-efficacy is a changeable psychological state
special attention should be paid to the time interval that
should be kept as short as possible (<two weeks). The
method for testing the validity depends on the aim of the
instrument. For example, the validity for instruments with
discriminative or planning aims can be tested cross-sec-
tionally whereas the validity for an instrument with an
evaluative aim should be tested in a longitudinal design.Health and Quality of Life Outcomes 2009, 7:86 http://www.hqlo.com/content/7/1/86
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Systematic approach for the development and validation of self-efficacy instruments: 5 steps for planning and reporting Figure 2
Systematic approach for the development and validation of self-efficacy instruments: 5 steps for planning and 
reporting.
A. Definition of 
aim of 
instrument
x Evaluative (detection of changes over time, typically for evaluation of 
treatments) 
x Discriminative (detection of differences between persons) 
x Predictive (prediction of future health outcomes, e.g. hospital admissions 
or death) 
x Planning (planning of treatment, e.g. detection of particular areas of low 
self-efficacy to target education accordingly) 
 B. Definition of 
a priori 
considerations
x Definition of domains (yes or no, number of domains, definition of 
domains) 
x Administration format (fully- or semi-structured questionnaire, self- or 
interviewer-administered) 
x Maximum time required for completion (<10 minutes) 
x Amenability to statistical analyses 
C. Identification 
of items
x Common sources: Patients (person-to-person, focus groups), literature 
search (systematic or unsystematic), experts, adaptation of existing 
instruments, patients’ relatives  => Recommendation: use of systematic 
literature search and focus groups with patients that includes cognitive 
debriefing 
x Properties of items are depending on aim of instrument: 
evaluative  discriminative  predictive  planning 
Properties 
of items 
detect
change 
over time 
distinguish
between 
persons 
distinction 
between 
patients
with and 
without
future
event
identification 
of areas of 
low
characteristic 
values to be 
targeted by 
treatment
D. Selection of 
items
x Common methods: data driven approach (e.g. use of statistical criteria 
such as factor analysis), patient approach (e.g. frequency of 
endorsement, comprehensibility of items), expert approach (e.g. 
estimation of relevance of items) 
x Assessment of measurement properties should be congruent with aim of 
instrument:  E. Validation of 
instrument 
evaluative  discriminative  predictive  planning 
Test-retest yes yes yes  yes 
Internal 
consistency 
yes yes yes  yes 
Validity  longitudinal 
validity
cross-sectional 
validity
calibration
1 cross-
sectional 
validity
Responsive-
ness 
yes -  -  - 
1 Calibration refers to the comparison of the proportion of events (e.g. hospital admission) 
predicted by the instrument and the proportion of events actually observed in the population. For 
further reading, please see Altman DG et al. British Medical Journal 2008, in press.Health and Quality of Life Outcomes 2009, 7:86 http://www.hqlo.com/content/7/1/86
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Testing responsiveness to change is important for instru-
ments with an evaluative aim, however, our systematic
review showed that neither responsiveness nor test-retest
reliability were consequently tested, although these meas-
urement properties are crucial for evaluative instruments.
Conclusion
The large number of available self-efficacy instruments
shows the growing interest in measuring self-efficacy in
patients with chronic diseases. However, the development
and validation process of the majority of these self-effi-
cacy instruments shows important limitations. Research-
ers in this important field should adhere more closely to
methodological concepts and report their methods more
transparently. Only thereby, potential users can make
informed decisions about which self-efficacy instrument
serves their purpose best.
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